Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

12.52
-0.7200-5.44%
Volume:1.19M
Turnover:15.26M
Market Cap:1.18B
PE:-3.97
High:13.74
Open:13.33
Low:12.40
Close:13.24
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:2.57
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.17
PE(LYR):-3.70

Loading ...

Wedbush Downgrades Replimune Group to Neutral From Outperform, Cuts Price Target to $2 From $19

MT Newswires Live
·
Apr 13

Replimune Group Cut to Sell From Buy by HC Wainwright & Co.

Dow Jones
·
Apr 13

Replimune downgraded to Sell from Buy at H.C. Wainwright

TIPRANKS
·
Apr 13

BUZZ-Replimune slumps after FDA drug rejection prompts downgrades

Reuters
·
Apr 13

Replimune Shares Decline 58% Premarket After at Least Two Brokerages Downgrade Stock After Advanced Skin Cancer Fails to Win FDA Nod

THOMSON REUTERS
·
Apr 13

Replimune Group Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Apr 13

Replimune downgraded to Hold from Buy at Jefferies

TIPRANKS
·
Apr 13

BRIEF-Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients

Reuters
·
Apr 11

Replimune says FDA’s CRL for RP1 ‘disappointing’

TIPRANKS
·
Apr 11

Replimune says FDA ‘appears to have contradicted their positions’ in CRL

TIPRANKS
·
Apr 11

Replimune Group: We Have No Choice but to Eliminate Jobs, Including Substantially Scaling Back Our U.S. Based Manufacturing Operations

THOMSON REUTERS
·
Apr 11

Replimune: Based on FDA Feedback, Started Ignyte-3 to Satisfy Regulatory Requirement That Confirmatory Study Be Underway for Accelerated Approval

THOMSON REUTERS
·
Apr 11

Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Apr 11

Replimune downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
Apr 11

Sector Update: Health Care Stocks Lower Friday Afternoon

MT Newswires Live
·
Apr 11

Replimune CRL positive for Iovance in near-term, says Chardan

TIPRANKS
·
Apr 11

Top Midday Decliners

MT Newswires Live
·
Apr 11

BRIEF-FDA Says Data Insufficient To Conclude Effectiveness Of Replimune's vusolimogene oderparepvec

Reuters
·
Apr 11

Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second Time -- Barrons.com

Dow Jones
·
Apr 11

Replimune's Biologics License Application for Advanced Cutaneous Melanoma Drug Rejected by FDA

MT Newswires Live
·
Apr 11